(Date:7/26/2008)...team develops device giving patients freedom of mo...DAY, July 26 (HealthDay News) -- An automated arti...e day be to dialysis patients what the insulin pum...rable artificial kidney (AWAK) works better than c...current issue of Clinical and Experimental Nephro...
(Date:7/25/2008)...AKE SUCCESS, N.Y., July 25 /PRNewswire-USNewswire/...as Chief Quality Officer and Vice President,of Str...monwealth Fund, a,national foundation committed to...e directed the foundation,s Program on Health Care...p://www.newscom.com/cgi-bin/prnh/20080725/DC28791L...
(Date:7/25/2008)...red immune response after antiretroviral therapy m... July 25 (HealthDay News) -- A new study challenge...(HCV) impairs the immune system,s ability to resto...ly active antiretroviral therapy (HAART). , Fro...ers are also infected with HCV. Intravenous drug u...
(Date:7/25/2008)...he Authority offers patients consumers tips and en...ient safety, HARRISBURG, Pa., July 25 /PRNewswire...thority today supports "National Patient Safety Da...s and their families to,participate fully in their...thing they can about their surgery or illness., "...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3...eloped a three-dimensional image of the AIDS virus...h aids in fusing// with human immune cells – An ex...agnosed. Findings from this AIDS research could ...ill thwart infection by targeting and crippling th...
... highly conducive for the cognitive development of...d//. Infact, even moderated alcohol intake during ... the unborn child. The study conducted by the Univ...ne and the University of Washington, has shown tha...
...the administration in WHO, to an agreement that wi...ent//. This is indeed a quantum leap in this field...ed. Moreover, it will also infuse renewed thrust i...h will in turn pave the way for novel methods to s...
...ing world statistics regarding the use of tobacco ...st one in five 13-15 year olds consume tobacco and...in the run up to the World Health Organization's W... years theme will revolve around the topic, ''toba...
Other Medicine News:Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 2Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 3(Date:7/24/2008)... /PRNewswire-USNewswire/ -- Headlines claiming "so...e story. The small scale,preliminary study that D...duction, is based on recollected intake of soyfood...This study is confounded by many,issues, thus I fe...of,caution," warned Dr. Tammy Hedlund, a researche...
(Date:7/24/2008)...rance, July 24 /- NicOx S.A...ne results from the 52-week,open label safety exte...of,the 301 phase 3 study for naproxcinod. The resu...icacy was maintained for the one-year duration of,...essment scale. In,addition, the results showed tha...
(Date:7/23/2008)... /PRNewswire-USNewswire/ -- The following was,rele... Conyers, Ranking Member Smith, and Members of the...fy today., Since I appeared before this Committee...acquainted with the talented and dedicated profess... they do, and I have come to,appreciate that much ...
(Date:7/23/2008)...RNewswire-FirstCall/ -- Dendreon Corporation,(Nasd...dependent Data,Monitoring Committee (IDMC) to revi... survival relating to the Company,s Phase 3 IMPACT...ent, also known as D9902B) clinical trial,of PROVE...nvestigational,active cellular immunotherapy for t...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Steps toward Stopping Autoimmune Disease 1967 1Steps toward Stopping Autoimmune Disease 1967 2CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 1CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 2Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 1Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 2Solutions for Parents Who Need Cold Remedies for Their Children 9795 1Solutions for Parents Who Need Cold Remedies for Their Children 9795 2...EGO, May 22, 2007 /PRNewswire/ -- A new study pres...iddle-of-the-night,balance, mobility or memory per...o placebo. This study also demonstrated, as in,pre... did have,impaired performances on these measures,...e-blind, placebo-controlled trial were,presented i...
... Release of Data for New Combination , , , , , P...cium channel blocker,amlodipine besylate with the ... produced significant mean reductions in,seated sy...th,hypertension, according to data presented at th...Second Annual Scientific Meeting and,Exposition (A...
Other Medicine Technology:New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 2New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 3New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 4Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 4Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
The Wet-Field Coagulator provides precise episcleral, intrascleral, and intraocular hemostasis with reduced peripheral tissue trauma. Controlled Rf diathermy delivers targeted coagulation with the mo
Medicine Products: